Home » Our Team » Julie DiStefano-Pappas

Julie DiStefano-Pappas

Project Director

With more than 20 years of experience in project and data management for clinical research studies, Julie DiStefano-Pappas serves as co-director of the Children’s Hospital of Philadelphia (CHOP)/Westat Biostatistics and Data Management Core. Ms. DiStefano-Pappas oversees clinical data managers, senior data research assistants, and data research assistants and serves as one of the main liaisons between CHOP leadership and Westat, focusing on business development strategy. Ms. DiStefano-Pappas also has experience managing phase 1-3 studies in rare disease.

Earlier in her career, Ms. DiStefano-Pappas worked as a clinical data manager at AstraZeneca Pharmaceuticals on global and North American phase III, IIIb, and IV studies of cardiovascular therapies. As a clinical data manager, she was responsible for case report form tracking, data review and validation, query generation and resolution, and reconciliation of adverse experience and serious adverse experience reports.

Selected Publications and Presentations

1.) Chung, D.C., McCague, S., Yu, Z.F., Thill, S., DiStefano-Pappas, J., Bennett, J., Cross, D., Marshall, K., Wellman, J., and High, K.A. (2018). Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clinical and Experimental Ophthalmology, 46(3), 247-259. doi: 10.1111/ceo.13022 PMID: 28697537

2.) Russell, S., Bennett, J., Wellman, J.A., Chung, D.C., Yu, Z.F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., Cross, D., Marshall, K., Walshire, J., Kehoe, T.L., Reichert, H., Davis, M., Raffini, L., George, L.A., Hudson, F.P., Dingfield, L., Zhu, X., Haller, J.A., Sohn, E.H., Mahajan, V.B., Pfeifer, W., Weckmann, M., Johnson, C., Gewaily, D., Drack, A., Stone, E., Wachtel, K., Simonelli, F., Leroy, B.P., Wright, J.F., High, K.A., and Maguire, A.M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet, 390(10097), 849-860. doi: 10.1016/S0140-6736(17)31868-8 PMID: 28712537

3.) Bennett, J., Wellman, J., Marshall, K.A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O.U., Chung, D.C., Sun, J., Wright, J.F., Cross, D.R., Aravand, P., Cyckowski, L.L., Bennicelli, J.L., Mingozzi, F., Auricchio, A., Pierce, E.A., Ruggiero, J., Leroy, B.P., Simonelli, F., High, K.A., and Maguire, A.M. (2016). Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. Lancet, 388(10045), 661-672. doi: 10.1016/S0140-6736(16)30371-3 PMID: 27375040

Education

BA, Psychology, University of Pennsylvania